---
title: "Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295972502.md"
description: "In Boston on August 14, 2026, Cue Biopharma, Inc. (Nasdaq: CUE), a company in the clinical stage of biopharmaceuticals focusing on innovative treatments for immune-related illnesses, disclosed its financial performance for the second quarter of 2026 along with notable recent accomplishments."
datetime: "2026-08-14T20:06:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295972502.md)
  - [en](https://longbridge.com/en/news/295972502.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295972502.md)
generator: "portal-rs"
---

# Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

In Boston on August 14, 2026, Cue Biopharma, Inc. (Nasdaq: CUE), a company in the clinical stage of biopharmaceuticals focusing on innovative treatments for immune-related illnesses, disclosed its financial performance for the second quarter of 2026 along with notable recent accomplishments.

### Related Stocks

- [CUE.US](https://longbridge.com/en/quote/CUE.US.md)

## Related News & Research

- [Northwestern Mutual Wealth Management Co. Sells 76,868 Shares of Cue Biopharma, Inc. $CUE](https://longbridge.com/en/news/298427697.md)
- [HPS/PayMedix Named a 2026 Best and Brightest Company to Work For](https://longbridge.com/en/news/298358823.md)
- [TENX: Levosimendan benefits PH-HFpEF patients with high disease burden, guiding a refined LEVEL-2 trial](https://longbridge.com/en/news/298456291.md)
- [Quoin says FDA grants rare pediatric disease designation for QRX003 in peeling skin syndrome](https://longbridge.com/en/news/298320213.md)
- [Annaly Capital declares Q3 2026 dividend of $0.75 per share](https://longbridge.com/en/news/298499808.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**